Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
BChE Inhibitor
BChE-IN-13 is a potent and selective inhibitor of Butyrylcholinesterase (BChE), targeting both equine and human forms with IC50 values of 0.22 μM and 0.016 μM, respectively. This orally active compound demonstrates significant potential for enhancing memory and cognitive functions, making it a valuable tool in Alzheimer's disease research. Its specificity for BChE positions it as a promising candidate for exploring therapeutic strategies in neurodegenerative disorders. -
AChE/BChE Inhibitor
AChE/BChE-IN-3 hydrochloride is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), exhibiting IC50 values of 6.08 μM against electric eel AChE and 0.383 μM against equine serum BChE. This compound is valuable for research focused on neurodegenerative diseases and cholinergic dysfunction, providing insights into the modulation of cholinergic signaling pathways. Its potent inhibitory effects make it a useful tool for studying enzyme kinetics and drug discovery related to cognitive decline. -
AchE Inhibitor
Icopezil is a selective inhibitor of acetylcholinesterase (AchE), a key enzyme involved in the hydrolysis of acetylcholine. Its ability to enhance cholinergic transmission makes it a valuable compound for research in Alzheimer's disease and other cognitive disorders. By increasing acetylcholine levels in the synaptic cleft, Icopezil offers potential insights into therapeutic strategies targeting cholinergic deficits in neurodegenerative conditions. -
Cholinesterase (ChE) Inhibitor
(+)-Balanophonin is a phenolic compound that functions as an inhibitor of cholinesterase (ChE). It exhibits significant biological activities, including antioxidant, anti-inflammatory, anticancer, and antineurodegenerative effects. This compound is useful in research aimed at understanding neurodegenerative diseases and exploring potential therapeutic strategies for conditions associated with cholinergic system dysfunction. -
BChE Inhibitor
BChE-IN-10 is a potent mixed-type inhibitor of butyrylcholinesterase (BChE), exhibiting an IC50 value of 6.4 μM. Isolated from Bletilla striata, this compound effectively modulates cholinergic activity and holds potential in the investigation of Alzheimer’s disease (AD) pathology. Its application in neurodegenerative research makes it a valuable tool for studying BChE-related mechanisms and therapeutic strategies. -
AChE Inhibitor
Hydrangenol 8-O-glucoside is an acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 22.66 μM. Isolated from Hydrangea macrophyllus, this compound exhibits significant activity in inhibiting the PCA (passive cutaneous anaphylaxis) reaction. Its properties make it a useful tool for research on neurodegenerative diseases and allergic responses. -
BChE Inhibitor
S16–1029 is a selective and orally active butyrylcholinesterase (BChE) inhibitor, exhibiting IC50 values of 11.35 nM for equine BChE and 48.1 nM for human BChE. This compound is capable of crossing the blood-brain barrier (BBB), enabling it to effectively target the central nervous system (CNS). S16–1029 serves as a valuable tool for research in Alzheimer's disease (AD), contributing to the understanding of cholinergic dysfunction in neurodegenerative conditions. -
BChE Inhibitor
BChE-IN-14 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 0.23 μM for equine BChE and 0.011 μM for human BChE. This compound exhibits favorable blood-brain barrier permeability and primary cell safety, making it suitable for in vivo studies. BChE-IN-14 has potential in restoring cognitive function, positioning it as a valuable tool for research into Alzheimer’s disease and related neurodegenerative conditions. -
Cholinesterase (ChE) Inhibitor
Mimopezil is a cholinesterase (ChE) inhibitor that converts to the active metabolite Huperzine A in aqueous conditions. This compound demonstrates significant biological activity by enhancing acetylcholine levels, which is relevant in research focused on neurodegenerative diseases. Although Mimopezil exhibits low bioavailability in vivo, its effective metabolism to Huperzine A leads to increased concentrations in the bloodstream, making it a valuable tool for studying cognitive function and synaptic transmission. -
AChE Inhibitor
(3β,5α,6α,16β)-8,14-Didehydrocevane-3,6,16,20-tetrol is an acetylcholinesterase (AChE) inhibitor. At a concentration of 100 μg/mL, this compound demonstrates an in vitro inhibition rate of 12% against AChE, highlighting its potential utility in studies related to neurodegenerative diseases and cognitive disorders. Its application in biochemical research may provide insights into AChE-related pathways and therapeutic targets. -
AChE Inhibitor
Monardic acid A is a selective inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 53.1 μM against AChE from electric eel. It displays weak inhibitory activity against human erythrocyte AChE (IC50 >100 μM) and negligible effects on butyrylcholinesterase (BChE). By inhibiting AChE activity, Monardic acid A effectively reduces acetylcholine breakdown, contributing to its anti-inflammatory properties and modulation of neurotransmitter release. This compound is sourced from lungwort (Pulmonaria officinalis) and thyme (Thymus gobicus), making it valuable for research in anti-inflammatory drug development and neurodegenerative disease therapeutics. -
Cholinesterase (ChE) Inhibitor
Isoprocarb-d3 is a deuterated form of Isoprocarb, a carbamate insecticide known for its efficacy in controlling pests such as rice paddy lice and leafhoppers. As an inhibitor of cholinesterase (ChE), Isoprocarb-d3 serves as a valuable tool in researching the mechanisms of action of carbamate insecticides and the effects of ChE inhibition. This compound can be utilized in studies related to pest management, neurobiology, and toxicology. -
Cholinesterase (ChE) Inhibitor
Drofenine is a potent competitive inhibitor of cholinesterase (ChE), with a Ki value of 3 μM. This compound effectively inhibits the breakdown of acetylcholine, leading to increased levels of this important neurotransmitter. Drofenine is utilized in research to study cholinergic signaling and its implications in neurodegenerative diseases, as well as to explore potential therapeutic avenues for conditions associated with impaired cholinergic transmission. -
BChE Inhibitor
BChE-IN-23 is a potent butyrylcholinesterase (BChE) inhibitor with an IC50 value of 21 nM. This compound is particularly valuable in Alzheimer's disease research, facilitating the study of cholinergic dysfunction associated with neurodegenerative conditions. Its selective inhibition of BChE may contribute to the development of therapeutic strategies for cognitive impairments in Alzheimer's disease. -
BuChE Inhibitor
BuChE-IN-4 is a selective butyrylcholinesterase (BuChE) inhibitor with an IC50 of 7.7 nM. It demonstrates mild antioxidant properties and neuroprotective effects while exhibiting a favorable lipophilicity and low toxicity profile. This compound is applicable in research focused on neurodegenerative diseases and exploring cholinergic signaling pathways. -
Acetylcholinesterase Inhibitor
Salithion is an acetylcholinesterase inhibitor that disrupts the hydrolysis of acetylcholine by binding to the enzyme's active site. This compound exhibits enantioselectivity, with distinct differences in the biological activity of its (R) and (S) enantiomers. Salithion serves as a valuable tool in neurotoxicology research and studies related to cholinergic signaling pathways. -
Cholinesterase (ChE) Inhibitor
AChE-IN-3 is a cholinesterase (ChE) inhibitor that demonstrates moderate inhibitory activity against acetylcholinesterase (AChE). Additionally, it exhibits strong nitric oxide (NO) inhibitory activity with an EC50 of 0.57 μM. This compound is suitable for research applications focused on neurodegenerative diseases and signaling pathways involving nitric oxide. -
Ach Inhibitor
AChE-IN-103 is a potent acetylcholinesterase (AChE) inhibitor that demonstrates log IC50 values of 1.477 and 2.2 in alignment models I and II, respectively. This compound plays a significant role in the research of Alzheimer’s disease, where it may help elucidate the mechanisms of cholinergic dysfunction. AChE-IN-103 is valuable for studies aimed at developing therapeutic strategies targeting cognitive decline associated with this neurodegenerative disorder. -
AChE Inhibitor
Pseudocoptisine acetate is a quaternary alkaloid derived from the benzylisoquinoline scaffold, isolated from Corydalis Tuber. It functions as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 of 12.8 μM. This compound demonstrates significant anti-inflammatory and anti-amnestic properties, making it valuable for research in neurodegenerative diseases and cognitive impairment studies. -
ChE Inhibitor
SM 10888 is a selective and orally active cholinesterase (ChE) inhibitor. By enhancing the release of acetylcholine in the brain, SM 10888 offers potential therapeutic benefits in the context of neurological disorders. This compound is particularly relevant for research focused on Alzheimer's disease and other cholinergic dysfunctions. -
BChE Inhibitor
BChE-IN-34 is a highly selective inhibitor of butyrylcholinesterase (BChE) with an IIC50 of 25 nM, demonstrating excellent selectivity over acetylcholinesterase. This compound exhibits neuroprotective and antioxidant properties, making it a valuable tool for research into neurodegenerative diseases and cholinergic signaling pathways. Its specificity and efficacy position BChE-IN-34 as a promising candidate for studying the therapeutic potential of targeting BChE in various biological contexts. -
AChE Inhibitor
Stacofylline hydrochloride is a potent inhibitor of acetylcholinesterase (AChE) with an IC50 range of 5-50 nM. This xanthine derivative exhibits notable anti-amnesic and promnesic effects, making it relevant for research into memory enhancement and cognitive function. Its pharmacological properties position it as a valuable tool in Alzheimer's disease studies and other neurological research applications. -
AChE/BChE/LOX Inhibitor
Decaffeoylacteoside is an inhibitor targeting acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and lipoxygenase (LOX). This compound exhibits moderate inhibitory activity, making it relevant for research into neurodegenerative diseases and inflammation. Its ability to modulate these enzymes provides potential applications in pharmacological studies aimed at developing therapeutic agents for conditions involving cholinergic dysregulation and oxidative stress. -
AChE/BChE Inhibitor
AChE-IN-15 is a reversible inhibitor of human acetylcholinesterase (huAChE) with an IC50 value of 6.8 μM and human butyrylcholinesterase (huBChE) with an IC50 value of 16.1 μM. This compound exhibits significant antioxidant activity and has potential applications in research related to Alzheimer's disease. AChE-IN-15 is a valuable tool for investigating cholinesterase inhibition and its role in neurodegeneration. -
Acetylcholinesterase inhibitor
AChE-IN-36 is a potent inhibitor of acetylcholinesterase, exhibiting an IC50 of 0.04 μM. This compound influences reactive oxygen species (ROS) levels and modulates the gene expression of NRF2, making it a valuable tool for studies on neurodegenerative diseases and oxidative stress responses. Its activity is relevant for research focused on cholinergic signaling and cellular antioxidant pathways. -
AChE Inhibitor
Ostruthol is a coumarin compound that functions as a potent inhibitor of acetylcholinesterase (AChE). This inhibition contributes to increased levels of acetylcholine, a neurotransmitter that may be diminished in neurodegenerative disorders. Ostruthol is primarily utilized in Alzheimer's disease research to explore its potential therapeutic effects and mechanisms of action. -
AChE Inhibitor
AChE-IN-20 is a potent acetylcholinesterase (AChE) inhibitor, demonstrating an IC50 value of 397.32 nM and a Ki value of 335.76 nM. In addition to its primary target, AChE-IN-20 exhibits significant inhibitory activity against human carbonic anhydrases I and II, and α-glucosidase, with IC50 values of 84.14 nM, 69.24 nM, and 52.08 nM, respectively. This compound is valuable for research into neurodegenerative diseases and enzymatic regulation, providing insights into potential therapeutic strategies. -
AChE Inhibitor
2,3,9,10-Tetrahydroxyberberine bromide is a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 7.8 μM. This compound also demonstrates significant free radical scavenging activity, as evidenced by an IC50 of 43 μM in the DPPH assay. It is particularly relevant for studies focusing on Alzheimer's disease research and the exploration of neuroprotective mechanisms. -
AChE Inhibitor
(Rac)-Sclerone is an acetylcholinesterase (AChE) inhibitor derived from the green husk of Carya illinoinensis. It demonstrates significant AChE inhibition with an IC50 value of 192.65 ± 10.12 μg/mL. This compound is utilized in research applications targeting Alzheimer's disease and other neurodegenerative disorders, where modulation of cholinergic activity is of interest. -
AChE Inhibitor
Epi-galantamine is a diastereomer of galantamine that functions as an acetylcholinesterase (AChE) inhibitor, demonstrating an EC50 of 45.7 μM. This alkaloid is extracted from the bulbs and flowers of Caucasian snowdrop (Galanthus woronowii). Epi-galantamine is notably utilized in research exploring neurodegenerative diseases and cognitive enhancement, contributing to studies on cholinergic signaling and potential therapeutic interventions. -
Cholinesterase Inhibitor
AChE-IN-41 is a cholinesterase inhibitor designed to enhance acetylcholine levels by preventing its breakdown. This hybrid compound of Galantamine and Memantine demonstrates significant inhibition of cholinesterase activity, offering valuable insights for neurological research. AChE-IN-41 exhibits enhanced plasma stability and similar microsomal stability in vitro, although it possesses a shorter half-life and faster clearance in vivo, making it suitable for studies on cholinergic signaling and potential therapeutic applications in neurodegenerative diseases. -
Cholinesterase (ChE) Inhibitor
eeAChE-IN-1 is a potent inhibitor of cholinesterase (ChE), exhibiting an IC50 value of 23 nM. This compound is valuable for research applications related to neurodegenerative disorders and the modulation of cholinergic signaling pathways. Its efficacy in inhibiting ChE makes it a significant tool for studying acetylcholine metabolism and related biological processes. -
AChE/BChE Inhibitor
AChE/BChE-IN-19 is a nicotinic hydrazide derivative that acts as an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 21.45 nM and 18.42 nM, respectively. This compound is particularly relevant for studies investigating cholinergic dysfunction in neurodegenerative diseases, such as Alzheimer's disease. Its potent inhibitory activity makes it a valuable tool for exploring therapeutic strategies targeting cholinergic pathways. -
AChE Inhibitor
Methyl ganoderate A acetonide is a lanostane triterpene that functions as a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 18.35 μM. This natural compound, extracted from the fruiting bodies of Ganoderma lucidum, is utilized in research efforts focused on Alzheimer's disease (AD). Its inhibition of AChE makes it a valuable tool for investigating therapeutic strategies for cognitive decline associated with neurodegenerative disorders. -
Cholinesterase (ChE) Inhibitor
Floramultine ((S)-Floramultine) is a reversible inhibitor of cholinesterase (ChE), demonstrating moderate potency and selectivity for various cholinesterase isoforms. This compound, derived from plant sources, exhibits significant cholinergic activity and can be utilized in research exploring the modulation of cholinergic neurotransmission. Applications include studies related to neurodegenerative disorders and the development of therapeutic agents targeting cholinergic dysfunction. -
BChE Inhibitor
Isograndifoliol is a selective inhibitor of butyrylcholinesterase (BChE) with an IC50 of 0.9 μM, demonstrating moderate inhibition of acetylcholinesterase (AChE) with an IC50 of 342.9 μM. This compound exhibits vasorelaxant properties and potential anti-tumor activity. Isograndifoliol is relevant for research focused on neurodegenerative diseases, particularly in studies targeting dementia. -
AChE Inhibitor
Heliosupine is a pyrrolizidine alkaloid that acts as an acetylcholinesterase (AChE) inhibitor, exhibiting a reported IC50 of 0.57 mM. This compound demonstrates significant biological activity by deterring generalist herbivores, making it a valuable tool in ecological and pharmacological research. Its AChE inhibitory properties may also have implications for the study of neurodegenerative diseases and chemical ecology. -
AChE Inhibitor
AChE-IN-47 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 0.24 μM. This compound effectively hinders the self-aggregation of amyloid β peptides, demonstrating neuroprotective properties. Additionally, AChE-IN-47 significantly reduces intracellular accumulation of reactive oxygen species, making it a valuable tool for research in neurodegenerative disease models and studies focused on oxidative stress. -
sEH/AChE Inhibitor
sEH/AChE-IN-1 is a dual inhibitor targeting soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). This compound exhibits significant biological activity in reducing neuroinflammation and memory impairment, making it a valuable tool for studying neurodegenerative diseases. Its application is particularly relevant in Alzheimer's disease research, where it may help elucidate disease mechanisms and potential therapeutic strategies. -
AChE Inhibitor
AChE-IN-10 is a highly effective inhibitor of acetylcholinesterase (AChE), with an IC50 value of 2.4 nM. This compound demonstrates significant neuroprotective effects by enhancing neuronal morphology and increasing cell viability, while also reducing tau phosphorylation at the S396 residue. Additionally, AChE-IN-10 has been shown to decrease amyloid aggregation in conjunction with AChE activity, making it a valuable tool for research in neurodegenerative diseases and cognitive disorders. -
BChE Inhibitor
BChE-IN-25 is a selective inhibitor of butyrylcholinesterase (BChE), exhibiting an inhibitory concentration (IC50) of 3.77 μM. This compound demonstrates a 22-fold selectivity for BChE over acetylcholinesterase (AChE), making it a valuable tool for research applications in neurobiology and therapeutic development targeting cholinergic dysfunction. Researchers can utilize BChE-IN-25 to investigate the role of BChE in various physiological and pathological processes. -
BChE Inhibitor
BChE-IN-38 is a potent butyrylcholinesterase (BChE) inhibitor demonstrating impressive Ki values of 62.05 nM for human carbonic anhydrase I (hCAI), 28.78 nM for human carbonic anhydrase II (hCAII), 14.09 nM for acetylcholinesterase (AChE), and 1.15 nM for BChE. In addition to its inhibitory effects, BChE-IN-38 exhibits notable cytotoxic activity. This compound is essential for research applications focusing on neurodegenerative disorders, drug development targeting cholinergic systems, and the study of enzyme inhibition mechanisms. -
AChE Inhibitor
Acotiamide-d6 is a deuterated form of Acotiamide, an orally active and first-in-class gastroprokinetic agent that acts as an acetylcholinesterase (AChE) inhibitor. This compound enhances gastrointestinal motility and is primarily used in research applications related to functional dyspepsia. Its unique isotopic labeling allows for advanced studies in pharmacokinetics and metabolic pathways, providing valuable insights into the drug's action and efficacy. -
AChE Inhibitor
Axillaridine A is an acetylcholinesterase (AChE) inhibitor derived from Sarcococca hookeriana var. digyna. It effectively inhibits the catalytic activity of AChE, making it a valuable tool in the study of neurodegenerative diseases and cognitive function. This compound has potential applications in research exploring the modulation of cholinergic signaling and therapeutic strategies for conditions such as Alzheimer's disease. -
Acetylcholinesterase Inhibitor
Quinolactacin A2 is an acetylcholinesterase inhibitor that effectively reduces the breakdown of acetylcholine, thereby enhancing cholinergic neurotransmission. Additionally, this compound has been shown to inhibit tumor necrosis factor (TNF) production, which may have implications in inflammatory and neurodegenerative research. Quinolactacin A2 is valuable in studies investigating cholinergic signalling and its role in various pathophysiological conditions. -
AChE Inhibitor
Arisugacin B is a selective acetylcholinesterase (AChE) inhibitor with potent oral bioactivity. Its mechanism of action involves the inhibition of AChE, which plays a crucial role in neurotransmission by regulating acetylcholine levels. This compound is useful in research applications focused on neurodegeneration and related disorders, offering insights into potential therapeutic strategies for conditions such as Alzheimer's disease. -
AChE Inhibitor
AE027 is a potent inhibitor of acetylcholinesterase (AChE), effectively targeting both wild-type and the resistant F348Y mutation, with IC50 values of 10 μM and 43 μM, respectively. This compound exhibits significant biological activity in blocking AChE, making it a valuable tool for research in neurodegenerative disorders and studies related to cholinergic signaling. AE027 provides potential insights into therapeutic strategies for conditions associated with AChE dysregulation. -
AChE Inhibitor
Undulatine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 7.4 μM. This compound is capable of crossing the blood-brain barrier through passive permeation, making it a valuable tool for investigating the pathophysiology of Alzheimer's disease. Its ability to modulate cholinergic activity positions Undulatine as a promising candidate for research into therapeutic strategies for neurodegenerative disorders. -
AChE Inhibitor
N-Methylcalycinine is a natural product that acts as an acetylcholinesterase (AChE) inhibitor. Isolated from the roots of Stephania epigaea, it possesses potential therapeutic implications in various research fields, including asthma, cancer, dysentery, fever, hyperglycemia, intestinal disorders, inflammation, sleep disturbances, and tuberculosis. This compound may be valuable for studies exploring its effects on neurotransmitter regulation and related biological processes. -
Acetylcholinesterase Inhibitor
Samioside is an acetylcholinesterase inhibitor primarily extracted from the plants Phlomis nissolii and P. capitata. It exhibits notable free-radical scavenging and antimicrobial properties, making it a valuable compound for biological research. Samioside is particularly relevant for studies investigating its potential anti-Alzheimer’s effects, offering insights into therapeutic avenues for neurodegenerative conditions.
